Get the Stockscreener App
3.265
9.83%
0.315
Tharimmune Inc stock is traded at $3.265, with a volume of 45.93M.
It is up +9.83% in the last 24 hours and up +11.34% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$2.95
Open:
$6.76
24h Volume:
45.93M
Relative Volume:
4.58
Market Cap:
$18.92M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.2569
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
+4.85%
1M Performance:
+11.34%
6M Performance:
+111.75%
1Y Performance:
+20.45%
1-Day Range:
$3.0101
$6.89
1-Week Range:
$2.85
$6.89
52-Week Range:
$0.952
$9.08
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
3.205 | 22.45M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.68 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.36 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.02 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.25 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.18 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tharimmune Inc Stock (THAR) Latest News
Tharimmune raises $540 million from ARK Invest, DRW, Kraken and others to build Canton Coin treasury - theblock.co
Gold Edges Higher; ISM Manufacturing PMI Falls In October - inkl
Tharimmune, Inc. announced that it expects to receive $504 million in funding - MarketScreener
DRW Leads $540 Million Private Placement in Digital Asset Firm - Bloomberg.com
Tharimmune Shares Rise After $540 Million Private Placement - MarketScreener
Tharimmune Stock Gains 30%, on $540M Capital Raise to Build Canton Coin Treasury Strategy - CoinDesk
Tharimmune Announces $540M Private Placement for Blockchain - TipRanks
Tharimmune raises $540 million for Canton blockchain strategy - Investing.com
Tharimmune stock soars after $540 million private placement for Canton Coin - Investing.com UK
Tharimmune raises $540 million for Canton Coin treasury strategy By Investing.com - Investing.com Nigeria
Tharimmune raises $540 million to acquire Canton Coin digital assets - Investing.com
Tharimmune raises $540 million for Canton Coin treasury strategy - Investing.com
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy - MarketScreener
Tharimmune (NASDAQ: THAR) ~$540M private placement led by DRW, Liberty City Ventures - Stock Titan
Using Bollinger Bands to evaluate Tharimmune Inc.Dip Buying & Short-Term Trading Alerts - newser.com
Does Tharimmune Inc. fit your quant trading modelWeekly Trade Review & Free Fast Entry Momentum Trade Alerts - newser.com
How resilient is Tharimmune Inc. stock in market downturns2025 Dividend Review & Free Daily Entry Point Trade Alerts - newser.com
Tharimmune Amends Warrants Agreement to Boost Liquidity - MSN
Tharimmune completes $450 million private placement to establish Canton token treasury - Bitget
What insider trading reveals about Tharimmune Inc. stockWeekly Market Outlook & Daily Price Action Insights - newser.com
Will Tharimmune Inc. stock sustain high P E ratios2025 Earnings Impact & Short-Term High Return Ideas - newser.com
What the charts say about Tharimmune Inc. todayTrade Entry Report & Consistent Profit Alerts - newser.com
Using data models to predict Tharimmune Inc. stock movementMarket Sentiment Report & Free Growth Oriented Trading Recommendations - newser.com
Will earnings trigger a reversal in Tharimmune Inc.Quarterly Investment Review & Safe Entry Trade Reports - newser.com
Will Tharimmune Inc. continue its uptrendWeekly Profit Summary & Weekly High Conviction Trade Ideas - newser.com
Why analysts upgrade Tharimmune Inc. stock2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Is Tharimmune Inc. stock attractive for retirement portfoliosPortfolio Growth Summary & Long-Term Growth Portfolio Plans - newser.com
Is Tharimmune Inc. still worth holding after the dipOil Prices & Low Drawdown Investment Strategies - newser.com
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments - Pueblo Chieftain
What analysts say about Tharimmune Inc stockSector-Based Investing & Maximize Returns With Insights - earlytimes.in
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):